Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.

Cagney DN, Lamba N, Montoya S, Li P, Besse L, Martin AM, Brigell RH, Catalano PJ, Brown PD, Leone JP, Tanguturi SK, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA.

Breast Cancer Res Treat. 2019 Jul;176(1):171-179. doi: 10.1007/s10549-019-05236-6. Epub 2019 Apr 13.

PMID:
30982195
2.

Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study.

Braunstein SE, London WB, Kreissman SG, Villablanca JG, Davidoff AM, DeSantes K, Castleberry RP, Murray K, Diller L, Matthay K, Cohn SL, Shulkin B, von Allmen D, Parisi MT, Van Ryn C, Park JR, La Quaglia MP, Haas-Kogan DA.

Pediatr Blood Cancer. 2019 Jul;66(7):e27736. doi: 10.1002/pbc.27736. Epub 2019 Apr 9.

PMID:
30968542
3.

Moody D. Wharam Jr, MD, FACR, FASTRO, July 22, 1941-August 10, 2018.

Jabbour SK, Timmerman RD, Raben D, DeWeese TL, Donaldson SS, Thomas P, Laurie F, Bishop-Jodoin M, Tarbell N, Wolden S, Halperin E, Constine LS, Haas-Kogan D, Marcus K, Freeman C, Terezakis S, Million L, Smith MA, Mendenhall NP, Marcus RB Jr, Cherlow J, Kalapurakal J, Breneman J, Yock T, MacDonald S, Laack N, Donahue B, Indelicato D, Michalski J, Perkins S, Kachnic L, Esiashvilli N, Roberts KB, FitzGerald TJ.

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1026-1030. doi: 10.1016/j.ijrobp.2019.01.004. Epub 2019 Mar 13. No abstract available.

PMID:
30900552
4.

Towards a standard of care in oncology for transgender patients.

Burns ZT, Bitterman DS, Liu KX, Terezakis SA, Neira PM, Haas-Kogan DA.

Lancet Oncol. 2019 Mar;20(3):331-333. doi: 10.1016/S1470-2045(18)30942-2. No abstract available.

PMID:
30842045
5.

Local control after brain-directed radiation in patients with cystic versus solid brain metastases.

Brigell RH, Cagney DN, Martin AM, Besse LA, Catalano PJ, Lee EQ, Wen PY, Brown PD, Phillips JG, Pashtan IM, Tanguturi SK, Haas-Kogan DA, Alexander BM, Aizer AA.

J Neurooncol. 2019 Apr;142(2):355-363. doi: 10.1007/s11060-019-03106-1. Epub 2019 Feb 4.

PMID:
30715665
6.

The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma.

Bhaskaran V, Nowicki MO, Idriss M, Jimenez MA, Lugli G, Hayes JL, Mahmoud AB, Zane RE, Passaro C, Ligon KL, Haas-Kogan D, Bronisz A, Godlewski J, Lawler SE, Chiocca EA, Peruzzi P.

Nat Commun. 2019 Jan 25;10(1):442. doi: 10.1038/s41467-019-08390-z.

7.

Risk stratification by somatic mutation burden in Ewing sarcoma.

Liu KX, Lamba N, Hwang WL, Niemierko A, DuBois SG, Haas-Kogan DA.

Cancer. 2019 Apr 15;125(8):1357-1364. doi: 10.1002/cncr.31919. Epub 2019 Jan 2.

PMID:
30602061
8.

Management of pediatric low-grade glioma.

de Blank P, Bandopadhayay P, Haas-Kogan D, Fouladi M, Fangusaro J.

Curr Opin Pediatr. 2019 Feb;31(1):21-27. doi: 10.1097/MOP.0000000000000717.

PMID:
30531227
9.

Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis.

Lamba N, Cagney DN, Brigell RH, Martin AM, Besse LA, Catalano PJ, Phillips JG, Pashtan IM, Bi WL, Claus EB, Golby AJ, Dunn IF, Smith TR, Tanguturi SK, Haas-Kogan DA, Alexander BM, Aizer AA.

World Neurosurg. 2019 Feb;122:e1557-e1561. doi: 10.1016/j.wneu.2018.11.100. Epub 2018 Nov 22.

PMID:
30471438
10.

Clinical Impact of Tumor Mutational Burden in Neuroblastoma.

Hwang WL, Wolfson RL, Niemierko A, Marcus KJ, DuBois SG, Haas-Kogan D.

J Natl Cancer Inst. 2018 Oct 10. doi: 10.1093/jnci/djy157. [Epub ahead of print]

PMID:
30307503
11.

Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.

Kline C, Liu SJ, Duriseti S, Banerjee A, Nicolaides T, Raber S, Gupta N, Haas-Kogan D, Braunstein S, Mueller S.

J Neurooncol. 2018 Dec;140(3):629-638. doi: 10.1007/s11060-018-2991-5. Epub 2018 Sep 11.

PMID:
30206764
12.

The Children's Oncology Group Radiation Oncology Discipline: 15 Years of Contributions to the Treatment of Childhood Cancer.

Breneman JC, Donaldson SS, Constine L, Merchant T, Marcus K, Paulino AC, Followill D, Mahajan A, Laack N, Esiashvili N, Haas-Kogan D, Laurie F, Olch A, Ulin K, Hodgson D, Yock TI, Terezakis S, Krasin M, Panoff J, Chuba P, Hua CH, Hess CB, Houghton PJ, Wolden S, Buchsbaum J, Fitzgerald TJ, Kalapurakal JA.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):860-874. doi: 10.1016/j.ijrobp.2018.03.002. Epub 2018 Mar 14. Review.

PMID:
29976498
13.

Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.

Pal S, Kozono D, Yang X, Fendler W, Fitts W, Ni J, Alberta JA, Zhao J, Liu KX, Bian J, Truffaux N, Weiss WA, Resnick AC, Bandopadhayay P, Ligon KL, DuBois SG, Mueller S, Chowdhury D, Haas-Kogan DA.

Cancer Res. 2018 Jul 15;78(14):4007-4021. doi: 10.1158/0008-5472.CAN-17-3691. Epub 2018 May 14.

14.

Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches-Meeting Viewpoint.

Ahmed MM, Coleman CN, Mendonca M, Bentzen S, Vikram B, Seltzer SM, Goodhead D, Obcemea C, Mohan R, Prise KM, Capala J, Citrin D, Kao G, Aryankalayil M, Eke I, Buchsbaum JC, Prasanna PGS, Liu FF, Le QT, Teicher B, Kirsch DG, Smart D, Tepper J, Formenti S, Haas-Kogan D, Raben D, Mitchell J.

Cancer Res. 2018 May 1;78(9):2166-2170. doi: 10.1158/0008-5472.CAN-17-3760. Epub 2018 Apr 23. No abstract available.

15.

National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury.

Haas-Kogan D, Indelicato D, Paganetti H, Esiashvili N, Mahajan A, Yock T, Flampouri S, MacDonald S, Fouladi M, Stephen K, Kalapurakal J, Terezakis S, Kooy H, Grosshans D, Makrigiorgos M, Mishra K, Poussaint TY, Cohen K, Fitzgerald T, Gondi V, Liu A, Michalski J, Mirkovic D, Mohan R, Perkins S, Wong K, Vikram B, Buchsbaum J, Kun L.

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):152-168. doi: 10.1016/j.ijrobp.2018.01.013. Review.

16.

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.

Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR.

Pediatr Blood Cancer. 2018 Jul;65(7):e27023. doi: 10.1002/pbc.27023. Epub 2018 Mar 30.

17.

Large Vessel Arteriopathy After Cranial Radiation Therapy in Pediatric Brain Tumor Survivors.

Nordstrom M, Felton E, Sear K, Tamrazi B, Torkildson J, Gauvain K, Haas-Kogan DA, Chen J, Buono BD, Banerjee A, Samuel D, Saloner D, Tian B, Roddy E, Hess C, Fullerton H, Mueller S.

J Child Neurol. 2018 Apr;33(5):359-366. doi: 10.1177/0883073818756729.

18.

Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation.

Cagney DN, Martin AM, Catalano PJ, Reitman ZJ, Mezochow GA, Lee EQ, Wen PY, Weiss SE, Brown PD, Ahluwalia MS, Arvold ND, Tanguturi SK, Haas-Kogan DA, Alexander BM, Redig AJ, Aizer AA.

Radiother Oncol. 2018 Mar;126(3):511-518. doi: 10.1016/j.radonc.2018.01.005. Epub 2018 Feb 3.

PMID:
29398153
19.

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways.

Jain P, Silva A, Han HJ, Lang SS, Zhu Y, Boucher K, Smith TE, Vakil A, Diviney P, Choudhari N, Raman P, Busch CM, Delaney T, Yang X, Olow AK, Mueller S, Haas-Kogan D, Fox E, Storm PB, Resnick AC, Waanders AJ.

Oncotarget. 2017 Sep 15;8(49):84697-84713. doi: 10.18632/oncotarget.20949. eCollection 2017 Oct 17.

20.

The Future of Radiobiology.

Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, Ma L, Marples B, Pajonk F, Park CC, Schaue D, Tran PT, Willers H, Wouters BG, Bernhard EJ.

J Natl Cancer Inst. 2018 Apr 1;110(4):329-340. doi: 10.1093/jnci/djx231.

21.

Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.

Narayan RS, Gasol A, Slangen PLG, Cornelissen FMG, Lagerweij T, Veldman HYYE, Dik R, van den Berg J, Slotman BJ, Würdinger T, Haas-Kogan DA, Stalpers LJA, Baumert BG, Westerman BA, Theys J, Sminia P.

Mol Cancer Ther. 2018 Feb;17(2):347-354. doi: 10.1158/1535-7163.MCT-17-0480. Epub 2017 Sep 27.

22.

Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma.

Campbell K, Karski EE, Olow A, Edmondson DA, Kohlgruber AC, Coleman M, Haas-Kogan DA, Matthay KK, DuBois SG.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):468-475. doi: 10.1016/j.ijrobp.2017.05.008. Epub 2017 May 15.

PMID:
28871998
23.

Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

Marini BL, Benitez LL, Zureick AH, Salloum R, Gauthier AC, Brown J, Wu YM, Robinson DR, Kumar C, Lonigro R, Vats P, Cao X, Kasaian K, Anderson B, Mullan B, Chandler B, Linzey JR, Camelo-Piragua SI, Venneti S, McKeever PE, McFadden KA, Lieberman AP, Brown N, Shao L, Leonard MAS, Junck L, McKean E, Maher CO, Garton HJL, Muraszko KM, Hervey-Jumper S, Mulcahy-Levy JM, Green A, Hoffman LM, Dorris K, Vitanza NA, Wang J, Schwartz J, Lulla R, Smiley NP, Bornhorst M, Haas-Kogan DA, Robertson PL, Chinnaiyan AM, Mody R, Koschmann C.

Transl Res. 2017 Oct;188:27.e1-27.e14. doi: 10.1016/j.trsl.2017.08.001. Epub 2017 Aug 10.

24.

Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.

Wahl M, Chang SM, Phillips JJ, Molinaro AM, Costello JF, Mazor T, Alexandrescu S, Lupo JM, Nelson SJ, Berger M, Prados M, Taylor JW, Butowski N, Clarke JL, Haas-Kogan D.

Cancer. 2017 Dec 1;123(23):4631-4639. doi: 10.1002/cncr.30909. Epub 2017 Jul 31.

25.

Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival.

Marinoff AE, Ma C, Guo D, Snuderl M, Wright KD, Manley PE, Al-Sayegh H, Sinai CE, Ullrich NJ, Marcus K, Haas-Kogan D, Goumnerova L, London WB, Kieran MW, Chi SN, Fangusaro J, Bandopadhayay P.

J Neurooncol. 2017 Oct;135(1):201-211. doi: 10.1007/s11060-017-2568-8. Epub 2017 Jul 21.

26.

Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI.

Anwar M, Molinaro AM, Morin O, Chang SM, Haas-Kogan DA, Nelson SJ, Lupo JM.

Radiat Res. 2017 Sep;188(3):303-313. doi: 10.1667/RR14662.1. Epub 2017 Jul 19.

27.

A Cautionary Tale: Risks of Radiation Therapy De-Escalation in Pediatric Malignancies.

Haas-Kogan DA, Devine CA, Liu KX, Terezakis SA.

J Clin Oncol. 2017 Aug 1;35(22):2471-2472. doi: 10.1200/JCO.2017.73.3485. Epub 2017 Jun 8. No abstract available.

PMID:
28594597
28.

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Kogan DA, Alexander BM, Aizer AA.

Neuro Oncol. 2017 Oct 19;19(11):1511-1521. doi: 10.1093/neuonc/nox077.

29.

Reply to J. Stenman et al.

La Quaglia MP, Haas-Kogan D, Park J, Kreissman SG, von Allmen D, Davidoff A, London WB, Khanna G.

J Clin Oncol. 2017 Jun 10;35(17):1966-1967. doi: 10.1200/JCO.2017.72.2777. Epub 2017 Apr 19. No abstract available.

PMID:
28422554
30.

Pediatric high-grade glioma: current molecular landscape and therapeutic approaches.

Braunstein S, Raleigh D, Bindra R, Mueller S, Haas-Kogan D.

J Neurooncol. 2017 Sep;134(3):541-549. doi: 10.1007/s11060-017-2393-0. Epub 2017 Mar 29. Review.

PMID:
28357536
31.

Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study.

Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA.

JAMA Oncol. 2017 Aug 1;3(8):1069-1077. doi: 10.1001/jamaoncol.2017.0001.

32.

A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.

Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, Truong AY, Cayanan G, Simonds EF, Haas-Kogan D, Phillips JJ, Nicolaides T, Okaniwa M, Shokat KM, Weiss WA.

Cancer Cell. 2017 Mar 13;31(3):424-435. doi: 10.1016/j.ccell.2017.01.014.

33.

Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation.

Li R, Polishchuk A, DuBois S, Hawkins R, Lee SW, Bagatell R, Shusterman S, Hill-Kayser C, Al-Sayegh H, Diller L, Haas-Kogan DA, Matthay KK, London WB, Marcus KJ.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):270-277. doi: 10.1016/j.ijrobp.2016.10.047. Epub 2016 Nov 8.

PMID:
28068235
34.

Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma.

von Allmen D, Davidoff AM, London WB, Van Ryn C, Haas-Kogan DA, Kreissman SG, Khanna G, Rosen N, Park JR, La Quaglia MP.

J Clin Oncol. 2017 Jan 10;35(2):208-216. Epub 2016 Nov 21.

35.

BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.

Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Stalpers LJ, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA.

Clin Cancer Res. 2016 Nov 1;22(21):5312-5321. Epub 2016 May 23.

36.

Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients.

Raleigh DR, Tomlin B, Buono BD, Roddy E, Sear K, Byer L, Felton E, Banerjee A, Torkildson J, Samuel D, Horn B, Braunstein SE, Haas-Kogan DA, Mueller S.

J Neurooncol. 2017 Jan;131(2):359-368. doi: 10.1007/s11060-016-2307-6. Epub 2016 Oct 24.

PMID:
27778212
37.

Pediatric low-grade gliomas: implications of the biologic era.

Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, Hwang E, Jabado N, Kilburn LB, Lassaletta A, Ligon KL, Massimino M, Meeteren SV, Mueller S, Nicolaides T, Perilongo G, Tabori U, Vezina G, Warren K, Witt O, Zhu Y, Jones DT, Kieran M.

Neuro Oncol. 2017 Jun 1;19(6):750-761. doi: 10.1093/neuonc/now209. Review.

38.

Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.

Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM.

Neuro Oncol. 2017 Feb 1;19(2):242-251. doi: 10.1093/neuonc/now176.

39.

Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors.

Roddy E, Sear K, Felton E, Tamrazi B, Gauvain K, Torkildson J, Buono BD, Samuel D, Haas-Kogan DA, Chen J, Goldsby RE, Banerjee A, Lupo JM, Molinaro AM, Fullerton HJ, Mueller S.

Neuro Oncol. 2016 Nov;18(11):1548-1558. Epub 2016 Aug 18.

40.

Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.

Hashizume R, Zhang A, Mueller S, Prados MD, Lulla RR, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD.

Neuro Oncol. 2016 Nov;18(11):1519-1528. Epub 2016 Jul 1.

41.

Pediatric high-grade glioma: biologically and clinically in need of new thinking.

Jones C, Karajannis MA, Jones DTW, Kieran MW, Monje M, Baker SJ, Becher OJ, Cho YJ, Gupta N, Hawkins C, Hargrave D, Haas-Kogan DA, Jabado N, Li XN, Mueller S, Nicolaides T, Packer RJ, Persson AI, Phillips JJ, Simonds EF, Stafford JM, Tang Y, Pfister SM, Weiss WA.

Neuro Oncol. 2017 Feb 1;19(2):153-161. doi: 10.1093/neuonc/now101. Review.

42.

Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome.

Raleigh DR, Solomon DA, Lloyd SA, Lazar A, Garcia MA, Sneed PK, Clarke JL, McDermott MW, Berger MS, Tihan T, Haas-Kogan DA.

Neuro Oncol. 2017 Jan;19(1):78-88. doi: 10.1093/neuonc/now105. Epub 2016 Jun 9. Erratum in: Neuro Oncol. 2017 Nov 29;19(12):1702.

43.

Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas.

Garcia MA, Solomon DA, Haas-Kogan DA.

Future Oncol. 2016 Jun;12(12):1493-506. doi: 10.2217/fon-2016-0039. Epub 2016 Apr 13. Review.

44.

Therapeutic radiation and the potential risk of second malignancies.

Kamran SC, Berrington de Gonzalez A, Ng A, Haas-Kogan D, Viswanathan AN.

Cancer. 2016 Jun 15;122(12):1809-21. doi: 10.1002/cncr.29841. Epub 2016 Mar 7. Review.

45.

MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism.

Bandopadhayay P, Ramkissoon LA, Jain P, Bergthold G, Wala J, Zeid R, Schumacher SE, Urbanski L, O'Rourke R, Gibson WJ, Pelton K, Ramkissoon SH, Han HJ, Zhu Y, Choudhari N, Silva A, Boucher K, Henn RE, Kang YJ, Knoff D, Paolella BR, Gladden-Young A, Varlet P, Pages M, Horowitz PM, Federation A, Malkin H, Tracy AA, Seepo S, Ducar M, Van Hummelen P, Santi M, Buccoliero AM, Scagnet M, Bowers DC, Giannini C, Puget S, Hawkins C, Tabori U, Klekner A, Bognar L, Burger PC, Eberhart C, Rodriguez FJ, Hill DA, Mueller S, Haas-Kogan DA, Phillips JJ, Santagata S, Stiles CD, Bradner JE, Jabado N, Goren A, Grill J, Ligon AH, Goumnerova L, Waanders AJ, Storm PB, Kieran MW, Ligon KL, Beroukhim R, Resnick AC.

Nat Genet. 2016 Mar;48(3):273-82. doi: 10.1038/ng.3500. Epub 2016 Feb 1.

46.

Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA.

J Neurooncol. 2016 Feb;126(3):395. doi: 10.1007/s11060-015-2024-6. No abstract available.

PMID:
26782702
47.

Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience.

Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA.

J Neurooncol. 2016 Jan;126(1):193-200. doi: 10.1007/s11060-015-1959-y.

48.

Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA.

J Neurooncol. 2016 Feb;126(3):385-93. doi: 10.1007/s11060-015-1939-2. Epub 2015 Sep 18. Erratum in: J Neurooncol. 2016 Feb;126(3):395.

49.

WEE1 Kinase As a Target for Cancer Therapy.

Mueller S, Haas-Kogan DA.

J Clin Oncol. 2015 Oct 20;33(30):3485-7. doi: 10.1200/JCO.2015.62.2290. Epub 2015 Jul 27. No abstract available.

PMID:
26215953
50.

Medical Student Perspectives on a Multi-institutional Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group.

Ye JC, Mohindra P, Spektor A, Krishnan MS, Chmura SJ, Howard AR, Viswanathan AN, MacDonald SM, Thaker NG, Das P, Mancini BR, Higgins SA, Braunstein S, Haas-Kogan D, Bradley KA, Hung AY, Thomas CR Jr, Kharofa J, Wheatley M, Currey A, Parashar B, Du K, Jimenez RB, Golden DW.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):217-9. doi: 10.1016/j.ijrobp.2015.01.043. No abstract available.

Supplemental Content

Loading ...
Support Center